Biogen (BIIB) said Wednesday that the US Food and Drug Administration has granted fast track designation to its investigational antisense oligonucleotide therapy BIIB080 aimed at treating Alzheimer's disease.
The company said BIIB080 is the first tau-targeting ASO therapy to enter clinical development for Alzheimer's and is currently being evaluated in a global phase 2 study in individuals with early-stage disease.
Biogen said the phase 2 trial is fully enrolled and a data readout is expected in 2026.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。